Results 91 to 100 of about 123,308 (219)
Engineering‐Modulated Molybdenum Enzymes Strategy for Tumor‐Specific Metabolic‐Immunotherapy
Biodegradable molybdenum sulfide nanoparticles were synthesized via a one‐pot strategy to increase molybdenum enzyme activity and thus effectively potentiate anti‐tumor immunity by integrating molybdenum‐based metalloimmunotherapy with hydrogen sulfide gas therapy.
Xiaoxiao Pan +14 more
wiley +1 more source
Rigidity‐tunable nanovesicle (P‐Pm) with mechanically induced adjuvanticity toward tumor‐associated macrophages (TAMs) was designed to engineer R848/gp100 antigen ‐loaded nanovaccine (P@Rg‐Pm), which achieved outstanding anti‐tumor outcomes in both therapeutic and preventive model of B16‐F10 melanoma.
Bangyue Luo, Liyan Qiu
wiley +1 more source
A high‐loading Zn single‐atom nanozyme (ZMG@CS) delivers ML‐SA5 and GOx to lysosomes. ML‐SA5 activates TRPML1 to release endogenous Zn2+, while the nanozyme provides exogenous Zn2+ and GOx‐driven acidification amplifies ROS production. Together, these effects suppress the HIF‐1α/GLUT1 axis, disrupt glucose and redox homeostasis, induce disulfidptosis ...
Zhenxin Wang +12 more
wiley +1 more source
Fibro‐adipogenic progenitors (FAPs) in atrophic muscle undergo YAP1‐driven pathogenic activation, secreting IL‐6 and FGF21 as bone‐catabolic myokines that mediate muscle‐bone crosstalk and promote bone loss. Genetic or pharmacological targeting of this YAP1‐FAP‐myokine axis rescues skeletal deterioration, identifying FAP‐derived myokines as therapeutic
Xiaoyu Cai +16 more
wiley +1 more source
Dual Lineages of Langerhans Cells Cooperate to Restore the Immune Barrier after Skin Injury
After skin injury, the epidermal immune barrier is rebuilt by two sources of Langerhans cells. Resident Langerhans cells first move into the wound during re‐epithelialization, guided by CXCR2 signaling. Later, recruited monocytes become long‐lived Langerhans cells.
Axel D. Schmitter‐Sánchez +8 more
wiley +1 more source
Combinations of small activating RNAs and small interfering RNAs were developed as personalized precision therapies that simultaneously activate tumor suppressors and silence oncogenes according to the molecular signatures of patient tumors. This combination strategy demonstrated superior anticancer efficacy, highlighting the promise of precision ...
Jing Wu +18 more
wiley +1 more source
A schematic model summarizing GNA15's mechanism in mediating macrophage M2 polarization and Gemcitabine resistance. ABSTRACT The complexity of pancreatic ductal adenocarcinoma (PDAC) progression, coupled with the lack of effective immunotherapy, underscores the imperative to deepen our understanding of its mechanisms and identify suitable immune ...
Weihui Guo +8 more
wiley +1 more source
LA‐LYTAC repurposes the cancer‐enriched amino acid transporter LAT1 as a lysosomal trafficking receptor for targeted membrane‐protein degradation. A single phenylalanine‐derived ligand, modularly linked to antibodies or small‐molecule binders, recruits PD‐L1, EGFR, or integrins to LAT1, triggering transporter‐mediated internalization, lysosomal ...
Liquan Zhu +12 more
wiley +1 more source
UFL1‐Mediated UFMylation of ENO1 Restrains Aerobic Glycolysis and Colorectal Cancer Progression
UFMylation restrains aerobic glycolysis and colorectal cancer progression by modifying the glycolytic enzyme ENO1. Pharmacological enhancement of the UFL1–ENO1 interaction by the FDA‐approved antibiotic torezolid promotes ENO1 UFMylation, suppresses tumor metabolism, and sensitizes colorectal cancer to chemotherapy, revealing an actionable metabolic ...
Xiuqing Ma +14 more
wiley +1 more source
This study developed an efficacy assessment platform that integrates patient‐derived gastric cancer organoids, atomic force microscopy (AFM)‐based nanomechanical vibration detection, deep learning analysis, and organoid mechanical modeling. It detects picomolar drug effects within 0.1 s signal, achieves 97% classification accuracy, and offers non ...
Ting Zhang +10 more
wiley +1 more source

